期刊文献+

结直肠癌原发灶与转移灶K-ras基因突变的比较分析 被引量:3

Evaluation of K-ras status concordance between primary colorectal cancer and related metastatic sites
下载PDF
导出
摘要 背景与目的:K-ras基因突变是抗表皮生长因子受体(epidermal growth factor receptor,EGFR)靶向治疗的重要负性预测因子。本研究拟对结直肠癌原发灶与转移灶中K-ras基因状态的一致性进行比较,以探讨目前临床K-ras检测的科学性与严谨性。方法:收集复旦大学附属肿瘤医院手术切除的结直肠癌原发灶及转移灶石蜡包埋组织76对,提取DNA,经过PCR扩增后,对产物进行基因序列分析,检测结直肠癌中K-ras基因外显子2基因序列。结果:76例患者中有15例结直肠癌原发灶与转移灶的K-ras基因突变情况不一致。76例结直肠癌原发灶有31例发生突变,突变率为40.8%,其中第13号密码子突变16例,第12号密码子突变15例;76例结直肠癌转移灶有31例发生突变,突变率为40.8%,其中第13号密码子突变15例,第12号密码子突变16例。结论:结直肠癌原发灶和转移灶中K-ras基因状态并不一致,且存在19.7%的表达差异率,提示通过检测原发灶K-ras基因表达状态来确定针对转移灶的西妥昔单克隆抗体药物选择存在不严谨性,需要进一步完善。 Background and purpose: Metastatic colorectal cancer (mCRC) patients with K-ras mutation won't benefit in the anti-epidermal growth factor receptor (EGFR) treatments. Thus K-ras mutation analysis is mandatory before this treatment. There is controversy that K-ras mutation analysis should be performed on primaries or related metastases. The aim of our study was to evaluate the concordance of K-ras status between primary and related metastases tumors, thus investigate the validity and rigorousness of clinical K-ras testing. Methods: Seventy-six patients with confirmed mCRC treated in Fudan University Shanghai Cancer Center were enrolled. After DNA extraction and PCR amplification, tumor specimens with paired primary tumors and related metastatic sites were put into sequencing analysis. And the K-ras mutation status in exon 2 was assessed. Results: K-ras mutation was detected in 31 out of 76 primary tumonrs (40.8%) and also 40.8% of the metastatic sites. But discordance was found between primary tumor and metastasis in 15 cases (19.7%): 8 primary tumors had a K-ras mutation with a wild- type metastasis, meanwhile 7 primary tumors were wild type with a K-ras-mutated metastasis. Conclusion: Our study indicated that quite a few mCRC cases have different K-ras status between primary tumors and related metastatic sites, and it's not very rigorous to choose the anti-EGFR treatments merely according to the primary tumor-K-ras mutation.Further study and consultation are needed on this problem.
出处 《中国癌症杂志》 CAS CSCD 北大核心 2013年第10期829-833,共5页 China Oncology
基金 上海市卫生局青年科研项目(No:2008Y079)
关键词 结直肠癌 K-RAS基因 原发灶 转移灶 西妥昔单抗 Colorectal cancer K-ras gene Primary tumor Metastases Cetuximab
  • 相关文献

参考文献19

  • 1FERLAY J, SHIN H R, BRAY F, et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008 [ J ] . Int J Cancer, 2010, 127(12): 2893-2917.
  • 2KARAPETIS C S, KHAMBATA-FORD S, JONKER D J, et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer [ J ] . N Engl J Med, 2008, 359(17): 1757- 1765.
  • 3COLICELLI J. Human RAS superfamily proteins and related GTPases [ J ] . Sci STKE, 2004, (250): 13.
  • 4SHIMIZU K, YUKAWA T, HIRAMI Y, et al. Heterogeneity of the EGFR mutation status between the primary tumor and metastatic lymph node and the sensitivity to EGFR tyrosine kinase inhibitor in non-small cell lung cancer [ J . Target Oncol, 2012. [ Epub ahead of print .
  • 5PEREZ K, WALSH R, BRILLIANT K, et al. Heterogeneity of eolorectal cancer (CRC) in reference to KRAS proto-oncogene utilizing WAVE technology [ J ] . Exp Mol Pathol, 2013, 95(1): 74-82.
  • 6JULIEN S, MERINO-TRIGO A, LACROIX L, et al. Characterization of a large panel of patient-derived tumor xenografts representing the clinical heterogeneity of human colorectal cancer [ J ] . Clin Cancer Res, 2012, 18(19): 5314- 5328.
  • 7MEYERHARDT J A, MAYER R J. Systemic therapy for colorectal cancer [ J ] . N Engl J Med, 2005, 352(5): 476- 487.
  • 8SOBRERO A F, MAUREL J, FEHRENBACHER L, et al. EPIC: phase III trial of eetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic eolorectal cancer [ J ] . J Clin Oncol, 2008, 26(14): 2311-2319.
  • 9KIM M J, LEE H S, KIM J H, et al. Different metastatic pattern according to the KRAS mutational status and site- specific discordance of KRAS status in patients with colorectalcancer [ J ] . BMC Cancer, 2012, 12: 347.
  • 10FRANKLIN W A, HANEY J, SUGITA M, et al. KRAS mutation: comparison of testing methods and tissue sampling techniques in colon cancer [ J ] . J Mol Diagn, 2010, 12(1): 43-50.

二级参考文献4

共引文献49

同被引文献19

引证文献3

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部